Industry News
Biotechnology Industry News
Robert Abel of Schrödinger…
Robert Abel of Schrödinger discusses how AI and physics-based modeling are reshaping drug discovery.
Odyssey Therapeutics’ team of…
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D round after abandoning plans to go public this summer.
Protara applies modern science,…
Protara applies modern science, manufacturing, and regulatory expertise to reimagine proven medicines and deliver new treatment options for patients.
Capricor Therapeutics has publicly…
Capricor Therapeutics has publicly released its July response to the FDA's rejection of its Duchenne muscular dystrophy cell therapy deramiocel after the agency included deramiocel in a new batch of complete response letters (CRLs) released
Pfizer veteran Suneet Varma has…
Pfizer veteran Suneet Varma has found his next role. Months after leaving the Big Pharma, Varma has taken the CEO position at the newly created inflammation and immunology startup Intent Biologics.
Eli Lilly is inviting early-stage…
Eli Lilly is inviting early-stage biotechs to make use of drug discovery models that the pharma is providing via a new AI platform.
Novartis is paying $1.4 billion to…
Novartis is paying $1.4 billion to get its hands on Tourmaline Bio and its former Pfizer cardiovascular drug that impressed in a phase 2 study earlier this year.
The CNS-focused company is looking…
The CNS-focused company is looking to pull off the first biotech IPO since February and collect $228.5 million in much-needed funding for further clinical development of its schizophrenia candidate.
After previously delaying its…
After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for an ultra-rare pediatric mitochondrial disease.
Regeneron’s allergen-blocking…
Regeneron’s allergen-blocking antibodies have reduced the symptoms of cat and pollen allergies in a pair of phase 3 studies.
Dianthus Therapeutics is advancing…
Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase study.
Atom Therapeutics is touting data…
Atom Therapeutics is touting data from a phase 2b/3 study as evidence that its gout drug has the efficacy and safety profile to stand out from the competition.
A phase 2a trial of Rapport…
A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in the biotech up more than 157% in premarket trading.
Takeda and Alkermes both took data…
Takeda and Alkermes both took data from their orexin receptor 2 (OX2R)-selective agonists to Singapore this morning as the race to get a new class of narcolepsy drug approved heats up.
Junshi has announced that its…
Junshi has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval.
BioNTech and its new partner…
BioNTech and its new partner Bristol Myers Squibb have trotted out the first global data for their PD-L1xVEGF bispecific in small cell lung cancer. BioNTech’s chief medical officer, Özlem Türeci, M.D., described the findings as
Servier is souping up its…
Servier is souping up its neurology pipeline with a clinical-stage candidate for a rare genetic disease sourced from U.K. biotech Kaerus Bioscience. The French pharma is offering as much as $450 million for KER-0193, a
Partners Daiichi Sankyo and Merck…
Partners Daiichi Sankyo and Merck & Co. are sharing phase 2 data for their investigational antibody-drug conjugate, findings the partners think will help score accelerated approval in pre-treated small cell lung cancer.
The FDA’s ongoing effort to…
The FDA’s ongoing effort to establish a culture of “radical transparency” saw the agency publish another haul of complete response letters yesterday.
Braveheart Bio has waded into the…
Braveheart Bio has waded into the fight for a heart disease market, paying $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten.